Prognostic, Immunological, and Mutational Analysis of MTA2 in Pan-Cancer and Drug Screening for Hepatocellular Carcinoma
Open Access
- 24 May 2023
- journal article
- research article
- Published by MDPI AG in Biomolecules
- Vol. 13 (6) , 883
Abstract
Background: Metastasis-associated protein 2 (MTA2) is a member of the metastasis-associated transcriptional regulator family and is a core component of the nucleosome remodeling and histone deacetylation complex. Despite growing evidence that MTA2 plays a crucial role in the tumorigenesis of certain cancers, no systematic pan-cancer analysis of MTA2 is available to date. Therefore, the aim of our study is to explore the prognostic value of MTA2 in 33 cancer types and to investigate its potential immune function. Methods: by comprehensive use of databases from TCGA, GTEx, GEO, UCSC xena, cBioPortal, comPPI, GeneMANIA, TCIA, MSigDB, and PDB, we applied various bioinformatics approaches to investigate the potential role of MTA2, including analyzing the association of MTA2 with MSI, prognosis, gene mutation, and immune cell infiltration in different tumors. We constructed a nomogram in TCGA-LIHC, performed single-cell sequencing (scRNA-seq) analysis of MTA2 in hepatocellular carcinoma (HCC), and screened drugs for the treatment of HCC. Finally, immunohistochemical experiments were performed to verify the expression and prognostic value of MTA2 in HCC. In vitro experiments were employed to observe the growth inhibition effects of MK-886 on the HCC cell line HepG2. Results: The results suggested that MTA2 was highly expressed in most cancers, and MTA2 expression was associated with the prognosis of different cancers. In addition, MTA2 expression was associated with Tumor Mutation Burden (TMB) in 12 cancer types and MSI in 8 cancer types. Immunoassays indicated that MTA2 positively correlated with activated memory CD4 T cells and M0 macrophage infiltration levels in HCC. ScRNA-seq analysis based on the GEO dataset discovered that MTA2 was significantly expressed in T cells in HCC. Finally, the eXtreme Sum (Xsum) algorithm was used to screen the antitumor drug MK-886, and the molecular docking technique was utilized to reveal the binding capacity between MK-886 and the MTA2 protein. The results demonstrated excellent binding sites between them, which bind to each other through Π-alkyl and alkyl interaction forces. An immunohistochemistry experiment showed that MTA2 protein was highly expressed in HCC, and high MTA2 expression was associated with poor survival in HCC patients. MK-886 significantly inhibited the proliferation and induced cell death of HepG2 cells in a dose-dependent manner. Conclusions: Our study demonstrated that MTA2 plays crucial roles in tumor progression and tumor immunity, and it could be used as a prognostic marker for various malignancies. MK-886 might be a powerful drug for HCC.Keywords
Funding Information
- Science and Technology Program of Zhanjiang (2019A01008, pdjh2022a0215, pdjh2023b0233, GDMU2021203, 2019KTSCX048)
- Scientific and Technological Innovation for Guangdong College Students (2019A01008, pdjh2022a0215, pdjh2023b0233, GDMU2021203, 2019KTSCX048)
- Innovation and Entrepreneurship project (2019A01008, pdjh2022a0215, pdjh2023b0233, GDMU2021203, 2019KTSCX048)
- Research Foundation from Department of Education of Guangdong Province (2019A01008, pdjh2022a0215, pdjh2023b0233, GDMU2021203, 2019KTSCX048)
This publication has 80 references indexed in Scilit:
- MTA2 promotes gastric cancer cells invasion and is transcriptionally regulated by Sp1Molecular Cancer, 2013
- NCBI GEO: archive for functional genomics data sets—updateNucleic Acids Research, 2012
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics DataCancer Discovery, 2012
- Overexpression of metastasis‐associated protein 2 is associated with hepatocellular carcinoma size and differentiationJournal of Gastroenterology and Hepatology, 2009
- Inactivation of NuRD Component Mta2 Causes Abnormal T Cell Activation and Lupus-like Autoimmune Disease in MiceJournal of Biological Chemistry, 2008
- MK-886 enhances tumour necrosis factor-α-induced differentiation and apoptosisCancer Letters, 2006
- Expression of MTA2 gene in ovarian epithelial cancer and its clinical implicationCurrent Medical Science, 2006
- Inhibitors of the Arachidonic Acid Pathway and Peroxisome Proliferator–Activated Receptor Ligands Have Superadditive Effects on Lung Cancer Growth InhibitionCancer Research, 2005
- Leukotriene B4 plays a pivotal role in CD40-dependent activation of chronic B lymphocytic leukemia cellsBlood, 2005
- Five‐lipoxygenase‐activating protein inhibitor MK‐886 induces apoptosis in gastric cancer through upregulation of p27kip1 and baxJournal of Gastroenterology and Hepatology, 2003